Remote Approaches for Evaluating Clinical Site Capabilities During Feasibility

Introduction: Shifting from On-Site to Remote Capability Assessments

The COVID-19 pandemic accelerated the adoption of remote and digital approaches in clinical research operations, including feasibility assessments and site qualification. Even post-pandemic, the use of remote methods to evaluate clinical site capabilities remains highly relevant due to cost savings, operational flexibility, and global trial complexity. Sponsors and CROs now conduct virtual site evaluations using teleconferencing, document sharing platforms, e-questionnaires, and remote facility walkthroughs to determine site readiness for clinical trials.

These remote methods must still comply with regulatory expectations and Good Clinical Practice (GCP) guidelines, while ensuring that sponsors adequately assess investigator qualifications, infrastructure, SOPs, technology readiness, and enrollment feasibility. This article provides a structured overview of remote methods for evaluating site capabilities, including benefits, limitations, digital tools, documentation practices, and best practices for inspection readiness.

1. Scope and Objectives of Remote Site Capability Assessments

Remote site assessments serve the same core purposes as on-site audits:

• Confirming investigator qualifications and experience
• Evaluating staffing, infrastructure, and SOP availability
• Reviewing technology readiness (e.g., EDC access, eConsent tools)
• Assessing enrollment potential and competing trial burden
• Ensuring regulatory and ethics committee preparedness

Remote assessments may be conducted as the sole method of feasibility or as a supplement to on-site audits, especially in decentralized, global, or hybrid trials.

2. Digital Tools and Platforms for Remote Evaluation

Several technologies enable effective remote feasibility and capability assessments:

• eFeasibility Platforms: Centralized systems for sending, collecting, and analyzing feasibility questionnaires (e.g., Clario, Veeva, TrialHub)
• Video Conferencing Tools: Used for live PI and staff interviews (e.g., Zoom, Microsoft Teams, Webex)
• Secure Document Sharing: For reviewing SOPs, CVs, calibration logs, and training records (e.g., SharePoint, Box, Dropbox Business)
• Virtual Facility Tours: Pre-recorded videos or live walkthroughs to inspect clinical and pharmacy areas
• Digital Signature Tools: For validating signed documents (e.g., DocuSign, Adobe Sign) compliant with 21 CFR Part 11

These tools must be validated where applicable and aligned with data privacy laws such as GDPR or HIPAA.

3. Components of a Remote Site Capability Assessment

During a remote feasibility process, sponsors should evaluate the following elements:

3.1 Investigator Qualifications and Oversight

• Request signed and dated CVs with therapeutic area experience
• Confirm GCP training within the past 24 months
• Schedule video interviews with PI and study coordinator
• Assess time allocation for trial and competing study load

3.2 Staffing and Infrastructure Review

• Request staffing matrix and delegation of duties template
• Collect site organizational chart and training logs
• Review equipment inventory and calibration certificates remotely
• Conduct virtual tour of IP storage room, exam rooms, lab areas

3.3 SOP and Quality Systems Documentation

• Request SOP index and sample SOPs (e.g., AE reporting, IP handling)
• Verify approval dates, version control, and review cycles
• Check SOP training records and acknowledgment logs

3.4 Technology Readiness

• Test access to sponsor platforms (EDC, IRT, eTMF)
• Verify internet stability and data security practices
• Assess familiarity with remote monitoring tools
• Ensure compatibility with eConsent, ePRO, and telehealth systems

3.5 Ethics Committee and Regulatory Preparedness

• Request past EC approval letters with turnaround times
• Confirm IRB registration status and contact details
• Discuss submission cycles and review schedules
• Clarify local regulatory steps, especially for global sites

4. Sample Remote Audit Summary Table

5. Regulatory Compliance in Remote Feasibility

Remote assessments must meet the same GCP and documentation requirements as in-person evaluations. Regulatory expectations include:

• Maintaining documented evidence of all remote assessments
• Version-controlled checklists and signed audit summaries
• Secure transmission and storage of shared files
• Recording video calls where permitted and logging attendance
• Ensuring systems used are Part 11 / Annex 11 compliant where applicable

The FDA, EMA, and MHRA have all published guidance supporting remote monitoring and oversight, especially in hybrid and decentralized models. Tools and processes used must be included in the sponsor’s TMF and internal SOPs.

6. Advantages of Remote Site Capability Assessments

• Cost-effective, especially for global and emerging markets
• Faster scheduling and turnaround time
• Enables review of more sites during early-stage feasibility
• Reduces travel burden and carbon footprint
• Supports decentralized trial models

7. Challenges and Limitations

• May miss facility details not visible via video
• Some sites lack technical capability or digital experience
• Potential data privacy risks during document sharing
• Subjective assessment of cleanliness, temperature logs, equipment state

Remote assessments may not fully replace on-site visits, especially for high-risk or first-time sites. A hybrid model may be more appropriate in such cases.

8. Best Practices for Remote Feasibility Teams

• Use a standardized remote audit checklist with clear pass/fail criteria
• Schedule structured video calls with predefined agenda
• Assign a tech coordinator to assist the site with video tours or file uploads
• Maintain a real-time tracker of document receipt and pending actions
• Ensure all activities are logged and archived in TMF with access audit trails

9. Real-World Example: Remote Assessment in Asia-Pacific Region

In a Phase III vaccine trial, a sponsor used remote feasibility methods to assess 28 sites across India, Vietnam, and Malaysia. The sponsor deployed eFeasibility tools and conducted structured Zoom interviews. While 5 sites were excluded due to lack of cold chain documentation or poor internet access, 23 were qualified and activated within 21 days—70% faster than previous trials. Remote methods enabled quick rollout while maintaining compliance and quality.

Conclusion

Remote methods for evaluating clinical site capabilities offer a flexible, scalable, and cost-effective alternative to traditional on-site audits. With the right tools, structured procedures, and documentation controls, sponsors and CROs can ensure a thorough and compliant feasibility process that supports modern clinical trial models. As digital trials continue to expand, remote feasibility will remain a core competency for clinical operations and regulatory teams alike.